Reviewed by Paul Tornambe, MD
Sometimes a single case example can provide food for thought and act as a springboard for future clinical studies. That’s exactly what Paul Tornambe, MD, of San Diego, hopes will happen from his findings on optical coherence tomography angiography (OCTA), choroidal neovascular membranes (CNVM), and treatment recommendations.
His case study results were presented at this year’s American Society of Retina Surgeons conference and suggested bringing a patient in 1 week after their first anti-vascular endothelial growth factor (VEGF) injection to undergo OCT can provide insights about the membrane and its likelihood to respond.
“The decision to start treatment, switch to another, or stop treatment altogether is sometimes arbitrary and capricious,” he said. “We really don’t know before starting treatment that this anti-VEGF drug works best for this specific neovascular membrane.”
Paul Tornambe, MD
E: [email protected]
Dr. Tornambe does not have any financial disclosures related to his comments.